IMV Inc. (NASDAQ:IMV) – Equities research analysts at Cantor Fitzgerald issued their FY2021 earnings per share estimates for IMV in a research report issued on Wednesday, September 22nd. Cantor Fitzgerald analyst B. Folkes anticipates that the company will post earnings of ($0.38) per share for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $4.00 price target on the stock. Cantor Fitzgerald also issued estimates for IMV’s FY2022 earnings at ($0.34) EPS.
IMV (NASDAQ:IMV) last released its earnings results on Wednesday, August 11th. The company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.12) by $0.01. The company had revenue of $0.04 million for the quarter. IMV had a negative net margin of 11,386.18% and a negative return on equity of 99.76%.
IMV stock opened at $1.72 on Friday. The firm’s fifty day simple moving average is $1.68 and its 200-day simple moving average is $2.29. The company has a market capitalization of $141.29 million, a P/E ratio of -4.10 and a beta of 1.51. The company has a debt-to-equity ratio of 0.38, a current ratio of 5.11 and a quick ratio of 5.11. IMV has a 12 month low of $1.31 and a 12 month high of $4.70.
Several institutional investors and hedge funds have recently bought and sold shares of the stock. First City Capital Management Inc. raised its position in IMV by 252.4% during the second quarter. First City Capital Management Inc. now owns 226,701 shares of the company’s stock worth $374,000 after acquiring an additional 162,365 shares during the period. Bank of Montreal Can raised its position in IMV by 59.5% during the first quarter. Bank of Montreal Can now owns 140,623 shares of the company’s stock worth $402,000 after acquiring an additional 52,445 shares during the period. Morgan Stanley raised its position in IMV by 13,722.0% during the second quarter. Morgan Stanley now owns 41,466 shares of the company’s stock worth $91,000 after acquiring an additional 41,166 shares during the period. JPMorgan Chase & Co. acquired a new position in IMV during the second quarter worth $88,000. Finally, LexAurum Advisors LLC acquired a new position in IMV during the second quarter worth $72,000. Hedge funds and other institutional investors own 11.01% of the company’s stock.
IMV Company Profile
IMV, Inc is a clinical-stage biopharmaceutical company that engages in providing a novel class of cancer immunotherapies and vaccines against infectious diseases including COVID-19. The company leverages its delivery platform (DPX) that programs immune cells directly within the human body to produce robust and sustained target killing capabilities.
Recommended Story: Day Trading
Receive News & Ratings for IMV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IMV and related companies with MarketBeat.com's FREE daily email newsletter.